ArticleiScience2026
Skipjack tuna bone-derived biocalcium ameliorates osteoblast and osteoclast differentiation through microRNA21 regulation.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative calcium sources are needed to enhance osteoporosis management. This study investigated the osteoprotective effects of skipjack tuna bone-derived biocalcium (Bio). Bio enhanced MC3T3-E1 osteoblast and C3H10T1/2 cell differentiation, increasing alkaline phosphatase activity and calcium deposition. Conversely, Bio inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in RAW 264.7 macrophages, reducing tartrate-resistant acid phosphatase (TRAP) activity and bone resorption. Bio suppressed intracellular ROS and downregulated primary, precursor and mature microRNA (miR)-21. miR-21 inhibitor suppressed TRAP activity and Cathepsin K expression, as opposed to miR-21 mimic. In an osteoblast-osteoclast crosstalk environment, Bio synergistically enhanced miR-21 target genes (PTEN and PDCD4) expression, whereas PTEN knockdown suppressed NFATc1 osteoclast marker expression via miR-21 inhibition. Molecular docking confirmed binding affinities between mouse and human miR-21 and both targets. Western blot showed β-catenin upregulation and total NF-κB p65 suppression after Bio treatment. Collectively, Bio exerts dual anti-osteoporotic actions, offering a potential functional supplement for bone remodeling disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.